HealthStream filings document the regulatory record for a Tennessee healthcare technology company listed on Nasdaq under HSTM. Its 8-K filings report quarterly and annual operating results, Regulation FD disclosures, dividend declarations, share repurchase programs, acquisitions and amendments to its revolving credit agreement.
The company’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items under its governance framework and incentive plans. Material-event filings also document executive appointments and related compensatory arrangements, while exhibits to current reports provide formal press releases and agreement summaries tied to HealthStream’s capital allocation, financing and workforce-technology operations.
Scott Fenstermacher, Senior Vice President at HealthStream, reported insider transactions dated 09/24/2025. The filing records a reported disposal of 16,026 shares of common stock and the acquisition of 1,552 restricted share units (RSUs) granted on 09/24/2025. Each RSU converts to one share upon vesting and the RSUs follow a four-year vesting schedule: 15% on 09/24/2026, 20% on 09/24/2027, 30% on 09/24/2028, and 35% on 09/24/2029. The RSUs were reported as beneficially owned following the transaction: 1,552 shares. The form is signed by Scott Fenstermacher on 09/26/2025.
Form 144 notice for HealthStream, Inc. (HSTM): an individual proposes to sell 2,000 shares of Common Stock through J.P. Morgan Securities LLC on 08/27/2025.
The filing states the shares were acquired as an RSU award from the issuer on 01/08/2025, paid in full on that date, and the reported aggregate market value of the proposed sale is $56,000. The filer reports 29,641,207 shares outstanding and discloses no sales by the holder in the prior three months. The filer certifies no undisclosed material adverse information.
HealthStream Inc. executive Kevin P. O'Hara reported the sale of 2,000 shares of the company's common stock on 08/27/2025, at a weighted average price of $27.9679 per share (individual trades ranged from $27.79 to $28.10). After the sale, Mr. O'Hara beneficially owned 17,137 shares. The Form 4 identifies Mr. O'Hara as an Executive Vice President and officer of the issuer and shows the filing was signed on 08/27/2025. The disclosure includes an agreement to provide trade-level detail on request and contains no derivative transactions or other securities reported on this form.